Transplantation Using Umbilical Cord And Placental Blood
- Determine the response rate of patients with chronic myeloid leukemia, acute leukemia,
lymphoma, myeloma, myelodysplasia, aplastic anemia, Fanconi's anemia, histiocytosis,
hereditary immunodeficiency, or storage disorder treated with allogeneic umbilical cord
and placental blood transplantation.
- Determine the toxicity of this regimen in these patients.
- Determine survival in these patients treated with this regimen.
- Determine the incidence of graft-versus-host disease in these patients treated with
OUTLINE: Patients receive a standard preparative regimen for their disease. Following the
preparative regimen patients undergo umbilical cord blood stem cell transplantation on day
Patients are followed every 1-2 weeks for 6 months.
PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study within 4-5 years.
Primary Purpose: Treatment
David G. Savage, MD
Herbert Irving Comprehensive Cancer Center
United States: Federal Government
|Herbert Irving Comprehensive Cancer Center at Columbia University||New York, New York 10032|